The TRANSFORM-HF study found no significant difference in outcomes between torsemide and furosemide treatments for heart failure. However, patients with de novo heart failure had better outcomes compared to those with worsening chronic heart failure after hospitalization. The study analyzed patients from 60 US hospitals and found that de novo heart failure was associated with decreased 12-month mortality, lower rehospitalization rates, and greater improvements in clinical summary scores compared to worsening chronic heart failure. No significant difference was found in outcomes between torsemide and furosemide treatments for either type of heart failure. The researchers noted that further investigation is needed due to the high mortality rate among patients with worsening chronic heart failure.
Source link
Torsemide, Furosemide Have Similar Outcomes in Patients Discharged With Acute HF
